Selected Grants
Maze Therapeutics MZE829-201: An Open-Label Phase 2 Study to Evaluate the Safety, Tolerability, and Effect on Albuminuria of MZE829 in Adults with Proteinuric Chronic Kidney Disease and the APOL1 High Risk Genotype
Clinical TrialPrincipal Investigator · Awarded by Maze Therapeutics · 2025 - 2030Endocrinology and Metabolism Training Program
Inst. Training Prgm or CMEMentor · Awarded by National Institute of Diabetes and Digestive and Kidney Diseases · 2024 - 2029Identification of Host-Specific Determinants of APOL1-associated COVAN
ResearchMentor · Awarded by National Institute of Diabetes and Digestive and Kidney Diseases · 2024 - 2029Duke Preparing Research Scholars in Biomedical Sciences- Post-Baccalaureate Research Education Program
Inst. Training Prgm or CMEMentor · Awarded by National Institute of General Medical Sciences · 2022 - 2027Mechanisms of HIV persistence in the kidney (R01)
ResearchCo-Principal Investigator · Awarded by National Institute of Diabetes and Digestive and Kidney Diseases · 2022 - 2027JAK-STAT Inhibition to Reduce Racial Disparities in Kidney Disease
ResearchPrincipal Investigator · Awarded by National Institute on Minority Health and Health Disparities · 2021 - 2027APOL1 Mediated Kidney Disease
ResearchPrincipal Investigator · Awarded by Alnylam Pharmaceuticals, Inc. · 2026 - 2027REGULATORS OF CALCINEURIN PATHWAYS AS DIAGNOSTIC AND THERAPEUTIC TARGETS FOR NEPHROTIC SYNDROME
ResearchInvestigator · Awarded by National Institutes of Health · 2023 - 2026Etiology of Persistent Microalbuminuria in Nigeria
ResearchInvestigator · Awarded by Vanderbilt University Medical Center · 2021 - 2026A-018101 Lilly USA
Clinical TrialPrincipal Investigator · Awarded by Lilly USA, LLC · 2022 - 2026NEPTUNE Public-Private Partnership ("MATCH Study")
ResearchPrincipal Investigator · Awarded by Regents of the University of Michigan · 2022 - 2025Nephrotic Syndrome Rare Disease Clinical Research Network III (NEPTUNE III) ("Study")
ResearchCo-Principal Investigator · Awarded by Regents of the University of Michigan · 2019 - 2025Alport Syndrome Natural History Ancillary Study
ResearchPrincipal Investigator · Awarded by Regents of the University of Michigan · 2023 - 2025Nephcure
ResearchPrincipal Investigator · Awarded by NEPHCURE Kidney International · 2023 - 2024Icagen SRA
ResearchPrincipal Investigator · Awarded by Icagen, Inc · 2021 - 2024A Study of the Prevalence of Apolipoprotein L1 (APOL1) Alleles Among Individuals With Proteinuric Kidney Disease Who Are of Recent African Ancestry or Geographic Origin
Clinical TrialPrincipal Investigator · Awarded by Vertex Pharmaceuticals Inc. · 2020 - 2024A Human Stem Cell-Derived Podocyte Model for APOL1 Nephropathy
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2019 - 2024Duke Training Grant in Nephrology
Inst. Training Prgm or CMEPreceptor · Awarded by National Institutes of Health · 1995 - 2023A Phase 2a, Open-label, Single-arm, 2-Part Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VX¿147 in Adults With APOL1-dependent Focal Segmental Glomerulosclerosis
Clinical TrialPrincipal Investigator · Awarded by Vertex Pharmaceuticals Inc. · 2020 - 2022A Natural History Study of Patients With Biopsy-proven Focal Segmental Glomerulosclerosis and Nephrotic Range Proteinuria Who Are of Recent African Ancestry or Have 2 APOL1 Risk Alleles
Clinical TrialPrincipal Investigator · Awarded by Vertex Pharmaceuticals Inc. · 2020 - 2022Unmasking the Molecular Mechanism of ApoL1 Nephropathy
ResearchPrincipal Investigator · Awarded by Robert Wood Johnson Foundation · 2020 - 2020External Relationships
- Maze Therapeutics
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.